Gamma-Aminobutyric Acid
CAS 56-12-2
Gamma-Aminobutyric Acid (CAS 56-12-2) is a Phase 1 pharmaceutical compound with 10 bioactivity targets and 60 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 6612.337482517482 nM | 102 | - |
| - | EC50 | 8582.611176470587 nM | 46 | - |
| - | Potency | 9703.114814814815 nM | 23 | - |
| - | Ki | 746 nM | 12 | - |
| - | Kd | 870.55 nM | 2 | - |
| - | AC50 | 31622.78 nM | 1 | - |
| Gamma-aminobutyric acid receptor subunit alpha-2 Ion channel |
IC50 | 7.66 | - | Rattus norvegicus |
| Sodium- and chloride-dependent GABA transporter 1 Transporter |
IC50 | 5.3 | - | Homo sapiens |
| Sodium- and chloride-dependent GABA transporter 1 Transporter |
IC50 | 5.59 | - | Rattus norvegicus |
| Sodium- and chloride-dependent GABA transporter 1 Transporter |
IC50 | 5.14 | - | Mus musculus |
| Gamma-aminobutyric acid receptor subunit alpha-1 Ion channel |
EC50 | 5 | - | Rattus norvegicus |
| Gamma-aminobutyric acid receptor subunit rho-1 Ion channel |
EC50 | 6.57 | - | Homo sapiens |
| Sodium- and chloride-dependent GABA transporter 3 Transporter |
IC50 | 5.15 | - | Homo sapiens |
| Sodium- and chloride-dependent betaine transporter Transporter |
IC50 | 4.44 | - | Homo sapiens |
| Sodium- and chloride-dependent GABA transporter 3 Transporter |
IC50 | 5.09 | - | Mus musculus |
| Sodium- and chloride-dependent GABA transporter 2 Transporter |
IC50 | 5.3 | - | Rattus norvegicus |
| Sodium- and chloride-dependent GABA transporter 2 Transporter |
IC50 | 4.56 | - | Mus musculus |
| Gamma-aminobutyric acid receptor subunit gamma-1 Ion channel |
IC50 | 7.48 | - | Rattus norvegicus |
| Platelet glycoprotein VI Unclassified |
Kd | 7.39 | - | Homo sapiens |
| Gamma-aminobutyric acid type B receptor subunit 1 GPCR |
IC50 | 4.6 | - | Rattus norvegicus |
| Sodium- and chloride-dependent GABA transporter 2 Transporter |
IC50 | 4.58 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Metal poisoning | 4 | 31.749 | 10027439 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| GABA B receptor GABBR1|GABBR2|KCTD8|KCTD12|KCTD16 |
Full agonist | 4.1 pKi | 11082110|12663046 |
| GABA B receptor Gabbr1|Gabbr2|Kctd8|Kctd12|Kctd16 |
Full agonist | 8.3 pIC50 | - |
| GABA B1 Gabbr1 |
Full agonist | 4.5 pIC50 | 9069281 |
| Glycine Receptor (All subtypes) | Partial agonist | 0.0 pEC50 | 11559772|8211147 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| .GAMMA.-AMINOBUTYRIC ACID | 4617 | SU | MTHSPL |
| gamma-aminobutyric acid | 4617 | PIN | RXNORM |
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Anaphylactic shock | gamma-aminobutyric | LLT | C0002792 |
| Anaphylactic shock | gamma-aminobutyric | PT | C0002792 |
| Angioedema | gamma-aminobutyric | LLT | C0002994 |
| Angioedema | gamma-aminobutyric | PT | C0002994 |
| Injection site pain | gamma-aminobutyric | PT | C0151828 |
| Injection site tenderness | gamma-aminobutyric | LLT | C0863083 |
| Pain | gamma-aminobutyric | LLT | C0030193 |
| Pain | gamma-aminobutyric | PT | C0030193 |
| Urticaria | gamma-aminobutyric | LLT | C0042109 |
| Urticaria | gamma-aminobutyric | PT | C0042109 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Gamma-Aminobutyric Acid used for in pharmaceutical contexts?
Gamma-Aminobutyric Acid (CAS 56-12-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Gamma-Aminobutyric Acid?
Gamma-Aminobutyric Acid has 60 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Metal poisoning, Condition aggravated, Product dose omission issue, Pruritus, Rash macular. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Gamma-Aminobutyric Acid also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for GABA (Gamma-Aminobutyric Acid) with EU status "permitted".
What clinical phase is Gamma-Aminobutyric Acid in?
Gamma-Aminobutyric Acid is rendered with ChEMBL max phase 1.
What bioactivity targets are documented for Gamma-Aminobutyric Acid?
Gamma-Aminobutyric Acid has 21 bioactivity rows in this page query. Rendered target entries include Gamma-aminobutyric acid receptor subunit alpha-2, Sodium- and chloride-dependent GABA transporter 1, Gamma-aminobutyric acid receptor subunit alpha-1, Gamma-aminobutyric acid receptor subunit rho-1, Sodium- and chloride-dependent GABA transporter 3.